News
MRK-WI
73.00
0.00%
0.00
AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty
Reuters · 32m ago
BUZZ-Revolution Medicines gains after report co in talks to be acquired by Merck
Reuters · 2h ago
MERCK & CO- CLEAR, EVIDENCE-BASED RECOMMENDATIONS NEEDED TO ENSURE CHILDREN & ADOLESCENTS RECEIVE RELIABLE PROTECTION AGAINST PREVENTABLE DISEASES
Reuters · 2h ago
MERCK & CO- AS HHS MAKES CHANGES TO THE IMMUNIZATION SCHEDULE, IT IS CRITICAL THAT CHANGES ARE INFORMED BY COMPREHENSIVE DATA
Reuters · 2h ago
PRICE TAG OF $28BN TO $32BN WAS BEING DISCUSSED AS PART OF MERCK-REVOLUTION MEDICINES DEAL - FT
Reuters · 3h ago
Merck in talks to buy biotech Revolution Medicines, Financial Times reports
Reuters · 3h ago
RPT- MERCK IN TALKS TO BUY CANCER DRUGMAKER REVOLUTION MEDICINES-FT
Reuters · 3h ago
SPIE Extends Multi-Technical Maintenance Contract with Merck for Molsheim Site
Reuters · 14h ago
MERCK & CO INC <MRK.N>: JEFFERIES CUTS TARGET PRICE TO $130 FROM $139
Reuters · 1d ago
MERCK & CO INC <MRK.N>: UBS RAISES TARGET PRICE TO $130 FROM $105
Reuters · 1d ago
VAXXAS APPOINTS FORMER MERCK GLOBAL VACCINES PRESIDENT DAVID PEACOCK AS CEO
Reuters · 1d ago
Merck Launches Phase 3 Trial of Calderasib and KEYTRUDA QLEX for KRAS G12C-Mutant Lung Cancer
Reuters · 1d ago
MERCK INITIATES PHASE 3 KANDLELIT-007 TRIAL EVALUATING CALDERASIB (MK-1084), AN INVESTIGATIONAL ORAL KRAS G12C INHIBITOR, IN COMBINATION WITH KEYTRUDA QLEX™ (PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH) IN CERTAIN PATIENTS WITH ADVANCED NSCLC
Reuters · 1d ago
Merck Completes Acquisition of Cidara Therapeutics
Reuters · 1d ago
MERCK TO COMPLETE ACQUISITION OF CIDARA THERAPEUTICS
Reuters · 1d ago
Merck & Co. Inc. to Hold Sales and Earnings Conference Call
Reuters · 1d ago
U.S. RESEARCH ROUNDUP-Alphabet, Hershey, Micron Technology
Reuters · 1d ago
BUZZ-Citi sees momentum in US pharma and biotech into 2026, updates ratings on top picks  
Reuters · 2d ago
MERCK & CO INC <MRK.N>: CITIGROUP RAISES TARGET PRICE TO $110 FROM $95
Reuters · 2d ago
U.S. RESEARCH ROUNDUP-Brunswick, Parker-Hannifin, XPLR Infrastructure
Reuters · 2d ago
More
Webull provides a variety of real-time MRK-WI stock news. You can receive the latest news about MERCK & CO through multiple platforms. This information may help you make smarter investment decisions.
About MRK-WI
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.